کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2154279 | 1090226 | 2011 | 7 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Radiochemotherapy of hepatocarcinoma via lentivirus–mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene Radiochemotherapy of hepatocarcinoma via lentivirus–mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene](/preview/png/2154279.png)
Herpes simplex virus thymidine kinase (HSV-TK) gene/ganciclovir (GCV) system has been widely used as a traditional gene therapy modality, and the sodium/iodide symporter gene (NIS) has been found to be a novel therapeutic gene. Since the therapeutic effects of radioiodine therapy or prodrug chemotherapy on cancers following NIS or HSV-TK gene transfer need to be enhanced, this study was designed to investigate the feasibility of radiochemotherapy for hepatocarcinoma via coexpression of NIS gene and HSV-TK gene.MethodsHepG2 cells were stably transfected with NIS, TK and GFP gene via recombinant lentiviral vector and named HepG2/NTG. Gene expression was examined by reverse transcriptase polymerase chain reaction, fluorescence imaging and iodide uptake. The therapeutic effects were assessed by MTT assay and clonogenic assay.ResultsHepG2/NTG cells concentrated 125I− up to 76-fold higher than the wild-type cells within 20 min, and the efflux happened with a T1/2eff of less than 10 min. The iodide uptake in HepG2/NTG cells was specifically inhibited by sodium perchlorate. Dose-dependent toxicity to HepG2/NTG cells by either GCV or 131I was revealed by clonogenic assay and MTT assay, respectively. The survival rate of HepG2/NTG cells decreased to 49.7%±2.5%, 43.4%±2.8% and 8.6%±1.2% after exposure to 131I, GCV and combined therapy, respectively.ConclusionWe demonstrate that radiochemotherapy of hepatocarcinoma via lentiviral-mediated coexpression of NIS gene and HSV-TK gene leads to stronger killing effect than single treatment, and in vivo studies are needed to verify these findings.
Journal: Nuclear Medicine and Biology - Volume 38, Issue 5, July 2011, Pages 757–763